Trials / Not Yet Recruiting
Not Yet RecruitingNCT07345741
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Donghua Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). To preliminarily determine the Maximum Tolerated Dose (MTD) or recommended clinical dose of AcNK-Sup003 cell injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AcNK-Sup003 cell injection | AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
- First posted
- 2026-01-16
- Last updated
- 2026-01-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07345741. Inclusion in this directory is not an endorsement.